EcoDrugPlus

5-Hydroxytryptamine Receptor 1f

Ensembl ID : ENSTRUG00000003117
Gene Symbol: HTR1F
1 Cross references
140 Possible Orthologues:

5-Hydroxytryptamine Receptor 2b

Ensembl ID : ENSTRUG00000017403
Gene Symbol: HTR2B
3 Cross references
202 Possible Orthologues:

5-Hydroxytryptamine Receptor 2c-Like

Ensembl ID : ENSTRUG00000005007
Gene Symbol: LOC101072775
3 Cross references
202 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSTRUG00000013117
Gene Symbol: HTR3A
1 Cross references
203 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSTRUG00000001258
Gene Symbol: HTR4
3 Cross references
198 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSTRUG00000017860
Gene Symbol: HTR5A
3 Cross references
209 Possible Orthologues:

5-Hydroxytryptamine Receptor 6

Ensembl ID : ENSTRUG00000008418
Gene Symbol: HTR6
3 Cross references
114 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSTRUG00000007675
Gene Symbol: HTR7
3 Cross references
196 Possible Orthologues:

60s Acidic Ribosomal Protein P1-Like

Ensembl ID : ENSTRUG00000005235
Gene Symbol: LOC101078882
4 Cross references
377 Possible Orthologues:

60s Ribosomal Protein L10

Ensembl ID : ENSTRUG00000023282
Gene Symbol: LOC101069574
4 Cross references
408 Possible Orthologues:

60s Ribosomal Protein L26

Ensembl ID : ENSTRUG00000032099
Gene Symbol: LOC101067942
3 Cross references
477 Possible Orthologues:

60s Ribosomal Protein L5

Ensembl ID : ENSTRUG00000000524
Gene Symbol: LOC101078338
3 Cross references
455 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).